Crescendo Biologics, a clinical stage immuno-oncology company developing novel, targeted T cell enhancing therapeutics, has been awarded the 'Best Established Biotech Company' award at the OBN Awards.
The company was reportedly nominated for its strong progress throughout the last several years, including the initiation of the clinical programme of CB307, a novel half-life extended CD137 x PSMA Humabody, as well as numerous milestones including within collaborations with Takeda and Zai Lab.
Theodora Harold, CEO of Crescendo, said: “We are honoured that our achievements have been recognised by the judging panel at this year’s OBN Awards. It is a testament to our team’s hard work in developing our portfolio of T cell enhancing therapies for the benefit of cancer patients. We are very proud to receive the industry-wide recognition and to be part of such a vibrant community of exciting bioscience companies.”
The OBN Award ceremony was held at the University of Oxford’s Ashmolean Museum and included 36 short-listed companies across 11 categories. Other finalists for the award included Healx and C4X Discovery.
